Zhang Zi, Guo Zhihao, Tan Yaqian, Li Lu, Wang Zhanzhang, Wen Yuguan, Huang Shanqing, Shang Dewei
Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical University, Guangzhou, 510000, China.
Heliyon. 2024 Feb 1;10(3):e25231. doi: 10.1016/j.heliyon.2024.e25231. eCollection 2024 Feb 15.
Sertraline is a first-line SSRI for the treatment of depression and has the same effectiveness along with a superior safety profile compared to other medications. There are few population pharmacokinetic (PPK) studies of sertraline and a lack of studies in the Chinese population. Therefore, we performed a PPK analysis of Chinese patients treated with sertraline to identify factors that can influence drug exposure. In addition, the dosing and discontinuation regimen of sertraline when applied to adolescents was explored. Sertraline serum drug concentration data were collected from 140 hospitalized patients to generate a sertraline PPK dataset, and data evaluation and examination of the effects of covariates on drug exposure in the final model were performed using nonlinear mixed-effects models (NONMEM) and first-order conditional estimation with interaction (FOCE-I). Examining rational medication administration and rational withdrawal of sertraline based on significant covariates and final modeling. A one-compartment model with first-order absorption and elimination of sertraline was developed for Chinese patients with psychiatric disorders. Analysis of covariates revealed that age was a covariate that significantly affected sertraline CL/F (P < 0.01) and that sertraline clearance decreased progressively with aging, whereas other factors had no effect on CL/F and V/F of sertraline. In the age range of 11-79, there were 54 adolescent patients (about 1/3) aged 13-18 years, and the safe and effective optimal daily dose for adolescent patients based on the final model simulations was 50-250 mg/d. For adolescent patients, serum concentration fluctuations were moderate for OD doses of 50 mg and 100 mg, using a fixed dose-descent regimen. For patients with OD doses of 150-200 mg and BID doses of 100-200 mg, a more gradual decrease in serum concentration was achieved with a fixed dose interval of 7 or 14 days for 25 mg as the regimen of descent. To our knowledge, this may be the first PPK study of sertraline in Chinese patients. We found that age was an important factor affecting clearance in Chinese patients taking sertraline. Patients taking sertraline may be exposed to increased amounts of sertraline due to decreased clearance with increasing age. The rational dosing and safe discontinuation of sertraline in adolescent patients can be appropriately referenced to the results of the model simulation, thus providing assistance for individualized dosing in adolescents.
舍曲林是治疗抑郁症的一线选择性5-羟色胺再摄取抑制剂(SSRI),与其他药物相比,疗效相当,但安全性更佳。目前针对舍曲林的群体药代动力学(PPK)研究较少,且缺乏针对中国人群的研究。因此,我们对接受舍曲林治疗的中国患者进行了PPK分析,以确定可能影响药物暴露的因素。此外,还探讨了舍曲林应用于青少年时的给药和停药方案。从140例住院患者中收集舍曲林血清药物浓度数据,以生成舍曲林PPK数据集,并使用非线性混合效应模型(NONMEM)和带交互作用的一阶条件估计法(FOCE-I)对最终模型中协变量对药物暴露的影响进行数据评估和检验。根据显著的协变量和最终模型,研究舍曲林的合理用药和合理停药。针对患有精神疾病的中国患者,建立了一个具有一级吸收和消除的舍曲林单室模型。协变量分析显示,年龄是显著影响舍曲林CL/F的协变量(P<0.01),舍曲林清除率随年龄增长而逐渐降低,而其他因素对舍曲林的CL/F和V/F没有影响。在11至79岁的年龄范围内,有54例青少年患者(约占1/3)年龄在13至18岁之间,根据最终模型模拟,青少年患者的安全有效最佳日剂量为50-250mg/d。对于青少年患者,采用固定剂量递减方案时,50mg和100mg的日剂量血清浓度波动适中。对于日剂量为150-200mg和每日两次剂量为100-200mg的患者,以25mg为递减剂量,固定剂量间隔7天或14天,可使血清浓度更缓慢地下降。据我们所知,这可能是首次针对中国患者进行的舍曲林PPK研究。我们发现年龄是影响服用舍曲林的中国患者清除率的重要因素。随着年龄增长,清除率降低,服用舍曲林的患者可能会接触到更多量的舍曲林。青少年患者舍曲林的合理给药和安全停药可适当参考模型模拟结果,从而为青少年的个体化给药提供帮助。